Rankings

Market Cap
Revenue
Operating Income
CapEx
Total Assets
Net Assets
Cash on Hand

Sectors

Technology
Healthcare
Financial Services
Consumer Cyclical
Communication Services
Industrials
Consumer Defensive
Energy
Basic Materials
Real Estate
Utilities

Pages

Home
Earnings Calendar
All Sectors
Terms
Privacy

© 2026 Market Cap Arena. All rights reserved.v1.2.30

IBRX FY 2013 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$9B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$600,000

Gross Profit

$347,00057.8% margin

Operating Income

-$2M-378.2% margin

Net Income

-$2M-341.2% margin

EPS (Diluted)

$-0.01

Cash Flow

Operating Cash Flow

-$668,000

Free Cash Flow

-$671,000

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2M

Total Liabilities

$5M

Stockholders' Equity

-$3M

Cash & Equivalents

$350,000

← FY 2014 All Quarters